SCHEMBL923561

SCHEMBL923561

Fc1ccccc1Nc1ncnc2sc3c(c12)CCCC3

nearest known ligand 0.98

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FGFR1 P11362 3/20 0.98
MAPK1 P28482 4/20 0.66
MEN1 O00255 1/20 0.66
POLB P06746 1/20 0.66
HPGD P15428 1/20 0.66
KMT2A Q03164 1/20 0.66
MKNK1 Q9BUB5 5/20 0.65
MAPT P10636 6/20 0.63
RAF1 P04049 3/20 0.63
HTT P42858 3/20 0.63
EGFR P00533 3/20 0.63
MAP2K1 Q02750 1/20 0.63
SMN1; SMN2 Q16637 1/20 0.63
GAA P10253 1/20 0.62
LMNA P02545 2/20 0.60
KDM4E B2RXH2 1/20 0.58
ALDH1A1 P00352 1/20 0.58
GLA P06280 1/20 0.58
PDE5A O76074 1/20 0.58
TP53 P04637 1/20 0.57

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3804176 0.82 FGFR1 (0.69) FGFR1MAPK1MEN1POLBHPGD
SCHEMBL4039669 0.82 MAPK1 (0.95) FGFR1MAPK1MEN1POLBHPGD
SCHEMBL3803059 0.80 FGFR1 (0.65) FGFR1MAPK1MEN1POLBHPGD
SCHEMBL923658 0.80 FGFR1 (1.00) FGFR1MAPK1MEN1POLBHPGD
SCHEMBL15427158 0.79 FGFR1 (0.64) FGFR1MAPK1MEN1POLBHPGD
SCHEMBL923247 0.79 MKNK1 (1.00) FGFR1MAPK1MEN1POLBHPGD
SCHEMBL2368492 0.78 FGFR1 (0.63) FGFR1MAPK1MEN1POLBHPGD
SCHEMBL12375312 0.78 MAPT (0.63) FGFR1MAPK1MEN1POLBHPGD
SCHEMBL925205 0.76 MKNK1 (0.79) FGFR1MAPK1MEN1POLBHPGD
SCHEMBL923228 0.75 MKNK1 (1.00) FGFR1MAPK1MEN1POLBHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8802849-B2 Tricyclic benzo[4,5]thieno-[2,3-d]pyrimidine-4-yl-amin derivatives, their salts, process for producing the compounds and their pharmaceutical use VICHEM CHEMIE KUTATÓ KFT. (HU) 2014-08-12 US claimed
US-20110015214-A1 TRICYCLIC BENZO[4,5]THIENO-[2,3-D]PYRIMIDINE-4-YL-AMIN DERIVATIVES, THEIR SALTS, PROCESS FOR PRODUCING THE COMPOUNDS AND THEIR PHARMACEUTICAL USE VICHEM CHEMIE KUTATO KFT. (HU) 2011-01-20 US claimed
EP-2257554-A1 TRICYCLIC BENZOÝ4,5¨THIENO-Ý2,3-D¨PYRIMIDINE-4-YL-AMIN DERIVATIVES, THEIR SALTS, PROCESS FOR PRODUCING THE COMPOUNDS AND THEIR PHARMACEUTICAL USE Vichem Chemie Kutató KFT (HU) 2010-12-08 EP claimed
WO-2009104026-A1 TRICYCLIC BENZO[4,5]THIENO-[2,3-D]PYRIMIDINE-4-YL-AMIN DERIVATIVES, THEIR SALTS, PROCESS FOR PRODUCING THE COMPOUNDS AND THEIR PHARMACEUTICAL USE VICHEM CHEMIE KUTATÓ KFT (HU) 2009-08-27 WO claimed
US-20110015214-A1 TRICYCLIC BENZO[4,5]THIENO-[2,3-D]PYRIMIDINE-4-YL-AMIN DERIVATIVES, THEIR SALTS, PROCESS FOR PRODUCING THE COMPOUNDS AND THEIR PHARMACEUTICAL USE VICHEM CHEMIE KUTATO KFT. (HU) 2011-01-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110015214-A1 TRICYCLIC BENZO[4,5]THIENO-[2,3-D]PYRIMIDINE-4-YL-AMIN DERIVATIVES, THEIR SALTS, PROCESS FOR PRODUCING THE COMPOUNDS AND THEIR PHARMACEUTICAL USE TYMS, TYMP, DPYD FGFR1 1511/4885MAPK1 3396/4885MEN1 3742/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.